Physicians should avoid prescribing it to: Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Individuals with severe gastrointestinal conditions, such as gastroparesis. Patients with a known allergy to GLP-1 receptor agonists. Pregnant or breastfeeding women, unless approved by a physician
Continuing treatment at a lower maintenance dose significantly reduces regain risk and preserves long-term results
It may be mild when you step up to a new dose, but it typically resolves faster (within days) than the initial adjustment
As for people who should not use epitalon, we know that this group includes women who are pregnant or breastfeeding , as there isnt enough research to confirm the safety of the mother, their fetus, or their developing child
Whilst Gamma-Butyrobetaine or GBB is a clinically trialed ingredient that has been proven to be a pre-cursor to L-Carnitine
The effect of semaglutide subcutaneous injection at 2.4 mg per week in patients with HFpEF and obesity (BMI 30 kg/m 2 ) but without diabetes was tested in STEP-HFpEF [29]
